Print Version |
Net sales during the three months ended
CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 41.6% to
We experienced a loss from operations during the three months ended September 30, 2024, primarily due to reduced sales and a change in sales mix from our private-label contract manufacturing segment and increased manufacturing costs. Manufacturing costs were negatively impacted by increased labor, supplies, rent, and freight costs. Although our overall sales forecast for fiscal 2025 includes a significant increase in sales as compared to fiscal 2024, we now anticipate we will experience a net loss in the first half of fiscal 2025, net income in the second half of fiscal 2025, and an overall net loss for the fiscal 2025 year.
As of
An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).
NAI, headquartered in
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our future revenue, profits and financial condition, as well as current and future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the
SOURCE -
CONTACT –
Web site: https://www.nai-online.com
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
(In thousands, except per share data) | |||||||||||||
(Unaudited) | |||||||||||||
Three Months Ended | |||||||||||||
2024 | 2023 | ||||||||||||
$ | 33,150 | 100.0 | % | $ | 33,969 | 100.0 | % | ||||||
Cost of goods sold | 30,891 | 93.2 | % | 30,832 | 90.8 | % | |||||||
Gross profit | 2,259 | 6.8 | % | 3,137 | 9.2 | % | |||||||
Selling, general & administrative expenses | 4,095 | 12.4 | % | 3,681 | 10.8 | % | |||||||
LOSS FROM OPERATIONS | (1,836 | ) | -5.5 | % | (544 | ) | -1.6 | % | |||||
Other expense, net | (577 | ) | -1.7 | % | (340 | ) | -1.0 | % | |||||
LOSS BEFORE TAXES | (2,413 | ) | -7.3 | % | (884 | ) | -2.6 | % | |||||
Income tax benefit | (431 | ) | (189 | ) | |||||||||
NET LOSS | $ | (1,982 | ) | $ | (695 | ) | |||||||
NET LOSS PER COMMON SHARE: | |||||||||||||
Basic: | ( |
) | ( |
) | |||||||||
Diluted: | ( |
) | ( |
) | |||||||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||||||||
Basic | 5,919 | 5,850 | |||||||||||
Diluted | 5,919 | 5,850 |
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands) | |||||||
2024 | 2024 | ||||||
(Unaudited) | |||||||
ASSETS | |||||||
Cash and cash equivalents | $ | 10,156 | $ | 11,981 | |||
Accounts receivable, net | 17,623 | 16,891 | |||||
Inventories, net | 25,927 | 24,249 | |||||
Other current assets | 8,775 | 8,489 | |||||
Total current assets | 62,481 | 61,610 | |||||
Property and equipment, net | 51,060 | 52,211 | |||||
Operating lease right-of-use assets | 42,919 | 43,537 | |||||
Other noncurrent assets, net | 4,810 | 4,984 | |||||
Total Assets | $ | 161,270 | $ | 162,342 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Accounts payable and accrued liabilities | 17,657 | 19,456 | |||||
Line of Credit | 5,400 | 3,400 | |||||
Mortgage note payable | 9,156 | 9,229 | |||||
Operating lease liability | 48,872 | 47,662 | |||||
Total Liabilities | 81,085 | 79,747 | |||||
Stockholders’ Equity | 80,185 | 82,595 | |||||
Total Liabilities and Stockholders’ Equity | $ | 161,270 | $ | 162,342 |
Source: Natural Alternatives International Inc